Ingalfarma is a biomedical company that develops innovative treatments aimed at solving complex oral pathologies. Its flagship product is Dentoxol, which is already available in Chile for purchase in specialty pharmacies. It is a topical solution designed for the prevention and control of oral mucositis, a pathology that generates painful ulcerative lesions in the oral cavity of cancer patients during and after chemo and radiation therapies. The company is currently carrying out Phase II trials and working on obtaining FDA approval for commercialization in the USA.